Effect of Phytoecdysterone Administration in Subjects With Prediabetes

NCT ID: NCT03906201

Last Updated: 2019-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-06

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prediabetes is the term used for people whose glucose levels do not meet the criteria for diabetes but are too high to be considered normal. This is defined by the presence of blood glucose between 100-125 mg / dL, values per glucose tolerance curve of 140-199mg / dL and/or HbA1c 5.7-6.4%. Prediabetes should not be considered as a clinical entity in itself, but as a risk factor for diabetes and cardiovascular disease (CVD). Prediabetes is associated with obesity (especially abdominal or visceral obesity), dyslipidemia with elevated triglycerides and/or low HDL cholesterol, and hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects with a diagnosis of prediabetes are included according to the criteria of the American Diabetes Association in its version 2019, between 30 and 60 years old residents of the city of Guadalajara, Jalisco, Mexico who come to clinical nutrition consultation in the University Hospital Fray Antonio Alcalde from the city of Guadalajara, Jalisco, Mexico.

The study design is a randomized, randomized clinical trial with a control group in two groups: an intervention group with ecdysterone 300mg every 24 hours for 12 weeks (approximately 90 days) and an approved placebo control group (magnesia stearate) ) at 300mg every 24 hours for 12 weeks (approximately 90 days).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PreDiabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

PreDiabetes Ecdysterone Genotoxicity Citotoxicity Micronuclei Glycemic Control

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

cohort populations with diagnostic metabolic syndrome treatment base with ecdysterone for 90 days
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Outcome Assessors
Randomized double-blind clinical trial plus control group

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 with placebo treatment

Group Type EXPERIMENTAL

Placebo

Intervention Type OTHER

no pharmacologic effect

Ecdysterone Group

Subjects diagnosed with prediabetes according to the criteria of the American Diabetes Association, version 2019 whit ecdysterone treatment

Group Type EXPERIMENTAL

Ecdysterone

Intervention Type DIETARY_SUPPLEMENT

Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ecdysterone

Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic

Intervention Type DIETARY_SUPPLEMENT

Placebo

no pharmacologic effect

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

magnesia stearate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \- Fasting Plasma Glucose between 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L)
2. \- Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L)
3. \- A1C 5.7-6.4% (39-47 mmol/mol).
4. \- Body Mass Index \>25 kg/m2 or \>23 kg/m2
5. \- Adults who have one or more of the following risk factors:

* First-degree relative with diabetes
* High-risk race/ethnicity
* History of CVD
6. \- Blood Pressure \<140/90 mmHg without therapy for hypertension
7. \- HDL cholesterol level \<0.35 mg/dL (0.90 mmol/L) and/or a triglyceride level \>0.250 mg/dL (2.82 mmol/L)

Exclusion Criteria

1.- Pregnant women or lactic period 2- Patients with some other chronic degenerative disease like diabetes mellitus 2 with pharmacologic treatment.

3.- Hypertension 4.- Cancer, 5.- Hyperthyroidism 6.- Hypothyroidism 7.- Immunologic disease 8.- Kidney disease 9.- Hepatic disease 10.- Cardiovascular disease 11- Abaqus activity 12.-Alcoholic activity.
Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Guadalajara

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ana Lilia Fletes Rayas

Reseach Professor Associated

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ANA FLETES

Role: PRINCIPAL_INVESTIGATOR

University of Guadalajara

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ana Fletes

Guadalajara, Jalisco, Mexico

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

ANA FLETES

Role: CONTACT

Phone: 011521-3310585200

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ANA FLETES

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Álvarez-Gasca Ma, Hernández-Pozo MR, Jiménez-Martínez M, Durán-Díaz A. Estilo de vida y presencia de síndrome metabólico en estudiantes universitarios. Diferencias por sexo. Rev de psicología. 2014; 32(1):121-138

Reference Type BACKGROUND

Andreassi MG, Barale R, Iozzo P, Picano E. The association of micronucleus frequency with obesity, diabetes and cardiovascular disease. Mutagenesis. 2011 Jan;26(1):77-83. doi: 10.1093/mutage/geq077.

Reference Type BACKGROUND
PMID: 21164186 (View on PubMed)

•Aparicio MR, Estrada LA, Fernández C, Hernández RM, Ruiz M, Ramos D, et al. Manual de antropometría. Instituto nacional de ciencias médicas y nutrición salvador zubirán: 2014 citar en:http://www.facmed.unam.mx/deptos/salud/censenanza/spi/unidad2/antropometria_manualinnsz.pdf

Reference Type BACKGROUND

Berti C, Riso P, Monti LD, Porrini M. In vitro starch digestibility and in vivo glucose response of gluten-free foods and their gluten counterparts. Eur J Nutr. 2004 Aug;43(4):198-204. doi: 10.1007/s00394-004-0459-1. Epub 2004 Jan 6.

Reference Type BACKGROUND
PMID: 15309439 (View on PubMed)

Graf BL, Poulev A, Kuhn P, Grace MH, Lila MA, Raskin I. Quinoa seeds leach phytoecdysteroids and other compounds with anti-diabetic properties. Food Chem. 2014 Nov 15;163:178-85. doi: 10.1016/j.foodchem.2014.04.088. Epub 2014 May 4.

Reference Type BACKGROUND
PMID: 24912714 (View on PubMed)

FAO, 2013. Food and agriculture organization of the united nations rome. Http://www.fao.org/docrep/018/i3300e/i3300e00.pdf

Reference Type BACKGROUND

FAO. Food and agriculture organization of the united nations 2011. La quinua: cultivo milenario para contribuir a la seguridad alimentaria mundial. Http://www.fao.org/docrep/017/aq287s/aq287s.pdf

Reference Type BACKGROUND

Figuerola F, Muñoz O, Estévez AM. La linaza como fuente de compuestos bioactivos para la elaboración de alimentos. Agro sur. 2008; 36(2): 49-58. Doi:10.4206/agrosur.2008.v36n2-01

Reference Type BACKGROUND

Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu l, et al. Encuesta nacional de salud y nutrición 2012. Resultados nacionales. Cuernavaca, méxico: instituto nacional de salud pública (mx), 2012

Reference Type BACKGROUND

Harishankar MK, Logeshwaran S, Sujeevan S, Aruljothi KN, Dannie MA, Devi A. Genotoxicity evaluation of metformin and glimepiride by micronucleus assay in exfoliated urothelial cells of type 2 diabetes mellitus patients. Food Chem Toxicol. 2015 Sep;83:146-50. doi: 10.1016/j.fct.2015.06.013. Epub 2015 Jun 24.

Reference Type BACKGROUND
PMID: 26115598 (View on PubMed)

Karaman A, Aydin H, Geckinli B, Cetinkaya A, Karaman S. DNA damage is increased in lymphocytes of patients with metabolic syndrome. Mutat Res Genet Toxicol Environ Mutagen. 2015 Apr;782:30-5. doi: 10.1016/j.mrgentox.2015.03.009. Epub 2015 Mar 13.

Reference Type BACKGROUND
PMID: 25868129 (View on PubMed)

Leon-Munoz LM, Guallar-Castillon P, Lopez Garcia E, Banegas JR, Gutierrez-Fisac JL, Rodriguez-Artalejo F. Relationship of BMI, waist circumference, and weight change with use of health services by older adults. Obes Res. 2005 Aug;13(8):1398-404. doi: 10.1038/oby.2005.169.

Reference Type BACKGROUND
PMID: 16129722 (View on PubMed)

Lizarzaburu-Robles JC. Síndrome metabólico: metabolicsyndrome: concept and practical application. An facmed. 2013;74(4):315-320.

Reference Type BACKGROUND

Kaufer-Horwitz M, Toussaint G. Indicadores antropométricos para evaluar sobrepeso y obesidad en pediatría. Bol. Med. Hosp. Infant. Mex; 2008;65(6): 502-518.

Reference Type BACKGROUND

Moreno-Altamirano l, García-García JJ, Soto-Estrada G, Capraro S, Limón-Cruz D. Epidemiología y determinantes sociales asociados a la obesidad y la diabetes tipo 2 en méxico. Revmedhosp gen méx. 2014; 77(3):86-95.

Reference Type BACKGROUND

Morris D, Vaisey-Genserb. Availability and labeling of flaxseedfood, products and supplements. In: thompson, l. U.; cunnane s. C. Flaxseed in human nutrition. 2003. 2nd edn., champaign, illinois. Aocs press. Pp. 404-422.

Reference Type BACKGROUND

Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008 Oct 8;269(2):315-25. doi: 10.1016/j.canlet.2008.03.046. Epub 2008 May 7.

Reference Type BACKGROUND
PMID: 18467024 (View on PubMed)

Ojeda-Lavin A. Proyecciones de la población 2010-2050. Consejo nacional de población méxico. 2014.http://www.conapo.gob.mx/es/conapo/proyecciones.

Reference Type BACKGROUND

Omsa. Datos y cifras. 10 datos sobre la obesidad. 2015. Disponible en: http://www.who.int/features/factfiles/obesity/facts/es/index1.html

Reference Type BACKGROUND

Cuevas ZO, Sangronis E. [Characterization of flaxseed (Linum usitatissimum L.) grown in Venezuela]. Arch Latinoam Nutr. 2012 Jun;62(2):192-200. Spanish.

Reference Type BACKGROUND
PMID: 23610908 (View on PubMed)

Penarrieta JM, Alvarado JA, Akesson B, Bergenstahl B. Total antioxidant capacity and content of flavonoids and other phenolic compounds in canihua (Chenopodium pallidicaule): an Andean pseudocereal. Mol Nutr Food Res. 2008 Jun;52(6):708-17. doi: 10.1002/mnfr.200700189.

Reference Type BACKGROUND
PMID: 18537130 (View on PubMed)

Rajesha J, Murthy KN, Kumar MK, Madhusudhan B, Ravishankar GA. Antioxidant potentials of flaxseed by in vivo model. J Agric Food Chem. 2006 May 31;54(11):3794-9. doi: 10.1021/jf053048a.

Reference Type BACKGROUND
PMID: 16719498 (View on PubMed)

Ramcharitar A, Badrie N, Mattfeldtbeman M, Matsuo H, Ridley C. Consumeracceptability of muffinswithflaxseed (linumusitatissimum). J. Foodsci 2005;70: 504-507.

Reference Type BACKGROUND

Ranilla LG, Apostolidis E, Genovese MI, Lajolo FM, Shetty K. Evaluation of indigenous grains from the Peruvian Andean region for antidiabetes and antihypertension potential using in vitro methods. J Med Food. 2009 Aug;12(4):704-13. doi: 10.1089/jmf.2008.0122.

Reference Type BACKGROUND
PMID: 19735168 (View on PubMed)

Repo-Carrasco-Valencia R, Hellströmb JK, Juha-Matti P, Mattila PH. Flavonoids and other phenolic compounds in andean indigenous grains: quinoa (chenopodium quinoa), kañiwa (chenopodium pallidicaule) and kiwicha (amaranthus caudatus). Food chemistry. 2010; 120(1):128-133.

Reference Type BACKGROUND

Shahidi F, Kim SK. Quality management of marine nutraceuticals. In: ho c-t, zheng qy, editors. Quality management of nutraceuticals. Acs symposium series 803. Washington, d.c.: american chemical society. 2002.p. 76-87.

Reference Type BACKGROUND

Spedding G, Ratty A, Middleton E Jr. Inhibition of reverse transcriptases by flavonoids. Antiviral Res. 1989 Sep;12(2):99-110. doi: 10.1016/0166-3542(89)90073-9.

Reference Type BACKGROUND
PMID: 2480745 (View on PubMed)

Stewart LK, Soileau JL, Ribnicky D, Wang ZQ, Raskin I, Poulev A, Majewski M, Cefalu WT, Gettys TW. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism. 2008 Jul;57(7 Suppl 1):S39-46. doi: 10.1016/j.metabol.2008.03.003.

Reference Type BACKGROUND
PMID: 18555853 (View on PubMed)

Torres-Bugarín O, Ramos-Ibarra ML. Utilidad de la prueba de micronúcleos y anormalidades nucleares en células exfoliadas de mucosa oral en la evaluación de daño genotóxico y citotóxico. Int. J. Morphol. 2013. 31(2):650-657.

Reference Type BACKGROUND

Torres-Bugarín O, Zavala-cerna MG, Macriz-Romero N, Flores-García A, Ramos-Ibarra ML. Procedimientos básicos de la prueba de micronúcleos y anormalidades nucleares en células exfoliadas de mucosa oral. El residente. 2013; (8):4-11.

Reference Type BACKGROUND

Voss S, Hesse A, Zimmermann DJ, Sauerbruch T, von Unruh GE. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol. 2006 May;175(5):1711-5. doi: 10.1016/S0022-5347(05)01001-3.

Reference Type BACKGROUND
PMID: 16600737 (View on PubMed)

Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I, Luo Y. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology. 2010 May;58(6):911-20. doi: 10.1016/j.neuropharm.2009.11.002. Epub 2009 Nov 14.

Reference Type BACKGROUND
PMID: 19917299 (View on PubMed)

Zimmet P, M M Alberti KG, Serrano Rios M. [A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results]. Rev Esp Cardiol. 2005 Dec;58(12):1371-6. No abstract available. Spanish.

Reference Type BACKGROUND
PMID: 16371194 (View on PubMed)

Zong G, Demark-Wahnefried W, Wu H, Lin X. Effects of flaxseed supplementation on erythrocyte fatty acids and multiple cardiometabolic biomarkers among Chinese with risk factors of metabolic syndrome. Eur J Nutr. 2013 Aug;52(5):1547-51. doi: 10.1007/s00394-012-0461-y. Epub 2012 Nov 23.

Reference Type BACKGROUND
PMID: 23179200 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://fmdiabetes.org/wp-content/uploads/2019/01/ada-2019.pdf

The journal of clinical and applied research and education. Diabetes Care. American Diabetes Association. Standards of Medical Care in Diabetes-2019.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

125/18

Identifier Type: -

Identifier Source: org_study_id